Analysis of Borrelia burgdorferi IgG antibodies with a combination of IgG ELISA and VlsE C6 peptide ELISA

Clinical Microbiology and Infection

Volumn 11, Issue 2, 2005, Pages 147-150

  Jansson, C ^a   Carlsson, S A ^a   Granlund, H ^a   Wahlberg, Peter ^a,b   Nyman, D ^a  

^a Aland Central Hospital   (Finland)

^b NONE   (Finland)

Author keywords

Antibody detection; Borrelia burgdorferi; C6 peptide; ELISA; IgC; Lyme disease

Indexed keywords

BACTERIAL PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; PROTEIN C6; PROTEIN VLSE; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ARTICLE; BLOOD SAMPLING; BORRELIA BURGDORFERI; CHI SQUARE TEST; COST BENEFIT ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INTERMETHOD COMPARISON; LYME DISEASE; MAJOR CLINICAL STUDY; PEPTIDE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; WESTERN BLOTTING;

BORRELIA; BORRELIA BURGDORFERI;

EID: 13844281072     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2004.01041.x     Document Type: Article

References (15)

1. Tugwell P, Dennis DT, Weinstein A et al. Laboratory evaluation in the diagnosis of Lyme disease. Ann Intern Med 1997; 127: 1109-1123.
2. Mochamuk RS, Rawlings J. Lyme disease: testing the waters. In: 14th International Scientific Conference on Lyme Disease and other Tick-borne Disorders, 2001. http://www.medscape.com/viewarticle/418439.
3. Centers for Disease Control and Prevention. Recommendations for test performance and interpretation from the second national conference on serologic diagnosis of Lyme disease. MMWR 1995; 44 590.
4. Wilske B, Zöller I, Brade V et al. Lyme-Borreliose. In: Mauch H, Lütticken R, Gatermann S, eds. Qualitätsstandards in der mikrobiologisch-infektiologischen diagnostik. München: Urban & Fischer Verlag, 2000; 1-59.
5. Hunfeld K-P, Stanek G, Straube E et al. Quality of Lyme disease serology. Wien Klin Wochenschr 2002; 114: 591-600.
6. Lawrenz MB, Hardham JM, Owens RT et al. Human antibody responses to VlsE antigenic variation protein of Borrelia burgdorferi. J Clin Microbiol 1999; 37: 3997-4004.
7. Schulte-Spechtel U, Lehnert G, Liegl G et al. Significant improvement of the recombinant Borrelia-specific immunoglobulin G immunoblot test by addition of VlsE and a DbpA homologue derived from Borrelia garinii for diagnosis of early neuroborreliosis. J Clin Microbiol 2003; 41: 1299-1303.
8. Bacon RM, Biggerstaff BJ, Schriefer ME et al. Serodiagnosis of Lyme disease by kinetic enzyme-linked immunosorbent assay using recombinant VlsE1 or peptide antigens of Borrelia burgdorferi compared with 2-tiered testing using whole-cell lysates. J Infect Dis 2003; 187: 1187-1199.
9. 6 peptide. J Neurol 2003; 250: 1318-1327.
10. Liang FT, Steere AC, Marques AR, Johnson BJB, Miller JN, Philipp M. Sensitive and specific serodiagnosis of Lyme disease by enzyme-linked immunosorbent assay with a peptide based on an immunodominant conserved region of Borrelia burgdorferi VlsE. J Clin Microbiol 1999; 37: 3990-3996.
11. Carlsson S-A, Granlund H, Nyman D, Wahlberg P. IgG seroprevalence of Lyme borreliosis in the population of the Åland Islands in Finland. Scand J Infect Dis 1998; 30: 501-503.
12. Anonymous. Manual for Immunetics® Quick ELISA™ C6 Borrelia assay kit. Cambridge, MA: Immunetics Inc., 2003.
13. Anonymous. Manual for RecomWell® Borrelia IgG™. Martinstried: Mikrogen GmbH, 2002.
14. Anonymous. Manual for RecomBlot® Borrelia IgG/IgM™. Martinstried: Mikrogen GmbH, 2002.
15. Hauser U, Lehnert G, Wilske B. Diagnostic value of proteins of three Borrelia species (Borrelia burgdorferi sensu lato) and implications for development and use of recombinant antigens for serodiagnosis of Lyme borreliosis in Europe. Clin Diagn Lab Immunol 1998; 5: 456-462.